Kodiak Sciences reported Phase 3 positive results in wet age-related macular degeneration, with its Zenkuda (tarcocimab tedromer) meeting non-inferiority versus aflibercept and with a dosing strategy that aimed to reduce injection frequency. In the DAYBREAK study, Kodiak said both tarcocimab tedromer and its IL-6/VEGF-trap bispecific tabirafusp-alpha-tedromer (KSI-501) met primary endpoints at one year. Kodiak also emphasized that more than half of patients reached a six-month dosing interval using an individualized re-treatment approach. The readout marks a major reversal after earlier trial setbacks and positions Kodiak to request FDA approval in the fourth quarter of 2026, with additional program datasets planned for later submissions. The results intensify competition for patients and providers seeking durability beyond standard Eylea schedules while maintaining visual acuity gains.